Naratriptan Orifarm

Naratriptan, the active ingredient in Naratriptan Orifarm, is a triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naratriptan Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class used for acute migraine management.

- Migraine: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: alleviates visual or sensory disturbances accompanying the attack. - Acute migraine attacks: aborts an ongoing migraine episode when taken early.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Paresthesia: tingling sensations. - Somnolence: mild drowsiness.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Arrhythmia: irregular heart rhythm. - Serotonin syndrome: severe reaction when combined with other serotonergic agents. - Severe hypertension: sudden high blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Myocardial infarction: rare heart attack.

Before using Naratriptan, consider the following safety points. - Cardiovascular disease: avoid if you have uncontrolled heart disease. - History of stroke or TIA: use with caution. - Concomitant MAO inhibitors: contraindicated due to serotonin risk. - Pregnancy: safety category unknown; discuss with a healthcare professional. - Liver impairment: dose adjustment may be required. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Naratriptan may interact with several medicines; review the following groups.

Major Interactions (Avoid): - MAO inhibitors: increase risk of serotonin syndrome. - Other triptans or ergot derivatives: may cause excessive vasoconstriction. - SSRIs/SNRIs: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure lowering. - Oral contraceptives: possible reduction in efficacy. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma levels.